CSIMarket
 


Coeptis Therapeutics Holdings Inc   (COEP)
Other Ticker:  
 

Cumulative Coeptis Therapeutics Holdings Inc 's Working Capital Ratio for Trailing Twelve Months Period

COEP's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

COEP Working Capital Ratio for Trailing Twelve Months Period

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Growth 38.46 % 10.6 % 95.09 % 52.72 % -56.84 %
Y / Y Current Assets Growth 33.18 % 13206.02 % 2988.48 % 949.66 % 855.16 %
Working Capital Ratio for Trailing Twelve Months Period 1.46 1.45 1.05 0.79 0.59
Total Ranking # 4423 # 4636 # 5469 # 5880 # 5639
Seq. Current Liabilities Growth 32.67 % -26.4 % 26.59 % 12.02 % 5.98 %
Seq. Current Assets Growth 27.41 % 8.51 % 66.84 % -42.26 % 12628.82 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2023
On the trailing twelve months basis Coeptis Therapeutics Holdings Inc Current Assets average grew by 33.18% in IV. Quarter year on year, faster than Current Liabilities, this led to increase in in Coeptis Therapeutics Holdings Inc 's Working Capital Ratio for Trailing Twelve Months Period to 1.46, Working Capital Ratio for Trailing Twelve Months Period remained below Coeptis Therapeutics Holdings Inc average.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry 157 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Coeptis Therapeutics Holdings Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about COEP
Working Capital Ratio COEP in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 158
Sector # 925
S&P 500 # 2578


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
1.65 0.62 0.09
(Sep 30 2023)   (Jun 30 2021)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Dec 31 2023, within Biotechnology & Pharmaceuticals Industry Working Capital Ratio for Trailing Twelve Months Period
Nanostring Technologies Inc   3.86 
Immunocore Holdings Plc  3.84 
Sana Biotechnology Inc   3.83 
Aligos Therapeutics Inc   3.80 
Erytech Pharma S a   3.65 
Qiagen N v   3.53 
Innate Pharma Sa  3.38 
Precision Biosciences Inc  3.38 
Arcellx Inc   3.36 
Adaptimmune Therapeutics Plc  3.25 
Seagen Inc   3.20 
Regenxbio Inc   3.16 
Biomx Inc   3.08 
Orchard Therapeutics Plc  2.99 
Moderna Inc   2.95 
Lineage Cell Therapeutics Inc   2.94 
Aptose Biosciences Inc   2.94 
Sangamo Therapeutics Inc   2.89 
Sqz Biotechnologies Company  2.88 
Tcr2 Therapeutics Inc   2.85 
Atara Biotherapeutics Inc   2.82 
Windtree Therapeutics Inc  2.79 
Xtant Medical Holdings Inc   2.76 
Neurocrine Biosciences Inc   2.72 
Gamida Cell Ltd   2.70 
Bluebird Bio Inc   2.65 
Repligen Corp  2.59 
Cellectis S a   2.54 
Tracon Pharmaceuticals Inc   2.38 
Biogen Inc   2.36 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com